Trial ID or NCT#

NCT03881696

Status

not recruiting iconNOT RECRUITING

Purpose

This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergic to more than two other foods, the primary endpoint/outcome in this study will only be assessed in peanut and two other foods for each participant. The primary objective of the study is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC), after treatment with either omalizumab or placebo for omalizumab.

Official Title

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11)

Eligibility Criteria

Ages Eligible for Study: 1 Year to 55 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

R. Sharon Chinthrajah
R. Sharon Chinthrajah
Associate Professor of Medicine (Pulmonary and Critical Care Medicine)

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM